From Conventional to Stealth Liposomes a new Frontier in Cancer Chemotherapy

Tumori - Tập 89 Số 3 - Trang 237-249 - 2003
Luigi Cattel1, Maurizio Ceruti1, Franco Dosio1
1Dipartimento di Scienza e Tecnologia del Farmaco, Università degli Studi di Torino, Italy

Tóm tắt

Many attempts have been made to achieve good selectivity to targeted tumor cells by preparing specialized carrier agents that are therapeutically profitable for anticancer therapy. Among these, liposomes are the most studied colloidal particles thus far applied in medicine and in particular in antitumor therapy. Although they were first described in the 1960s, only at the beginning of 1990s did the first therapeutic liposomes appear on the market. The first-generation liposomes (conventional liposomes) comprised a liposome-containing amphotericin B, Ambisome (Nexstar, Boulder, CO, USA), used as an antifungal drug, and Myocet (Elan Pharma Int, Princeton, NJ, USA), a doxorubicin-containing liposome, used in clinical trials to treat metastatic breast cancer. The second-generation liposomes (“pure lipid approach”) were long-circulating liposomes, such as Daunoxome, a daunorubicin-containing liposome approved in the US and Europe to treat AIDS-related Kaposi's sarcoma. The third-generation liposomes were surface-modified liposomes with gangliosides or sialic acid, which can evade the immune system responsible for removing liposomes from circulation. The fourth-generation liposomes, pegylated liposomal doxorubicin, were called “stealth liposomes” because of their ability to evade interception by the immune system, in the same way as the stealth bomber was able to evade radar. Actually, the only stealth liposome on the market is Caelyx/Doxil (Schering-Plough, Madison NJ, USA), used to cure AIDS-related Kaposi's sarcoma, resistant ovarian cancer and metastatic breast cancer. Pegylated liposomal doxorubicin is characterized by a very long-circulation half-life, favorable pharmacokinetic behavior and specific accumulation in tumor tissues. These features account for the much lower toxicity shown by Caelyx in comparison to free doxorubicin, in terms of cardiotoxicity, vesicant effects, nausea, vomiting and alopecia. Pegylated liposomal doxorubicin also appeared to be less myelotoxic than doxorubicin. Typical forms of toxicity associated to it are acute infusion reaction, mucositis and palmar plantar erythrodysesthesia, which occur especially at high doses or short dosing intervals. Active and cell targeted liposomes can be obtained by attaching some antigen-directed monoclonal antibodies (Moab or Moab fragments) or small proteins and molecules (folate, epidermal growth factor, transferrin) to the distal end of polyethylene glycol in pegylated liposomal doxorubicin. The most promising therapeutic application of liposomes is as non-viral vector agents in gene therapy, characterized by the use of cationic phospholipids complexed with the negatively charged DNA plasmid. The use of liposome formulations in local-regional anticancer therapy is also discussed. Finally, pegylated liposomal doxorubicin containing radionuclides are used in clinical trials as tumor-imaging agents or in positron emission tomography.

Từ khóa


Tài liệu tham khảo

Langer R., 1998, Nature,, 392, 5

10.1016/S0928-0987(00)00166-4

Cattel L., 1999, A review. STP Pharma Sci,, 9, 307

10.1021/bc970184f

10.1016/S0959-8049(99)00030-1

Frankel A.E., 2000, Clin Cancer Res,, 6, 326

10.1385/1-59259-167-1:289

Vasey P.A., 1999, Clin Cancer Res,, 5, 83

10.1016/S0378-5173(97)00135-X

Lundberg B., 1994, Anticancer Drug Des,, 9, 471

10.1016/0169-409X(95)00031-2

10.1038/42218

Bangham A.D., 1980, In: Liposomes in biological systems

10.1038/265407a0

Poste G., 1983, Biol Cell,, 47, 19

10.1111/j.1432-1033.1974.tb03681.x

10.1111/j.1749-6632.1985.tb18414.x

10.1016/0169-409X(96)00012-9

10.1016/0378-5173(95)04281-4

10.1016/S0168-3659(97)00045-X

10.1016/0169-409X(88)90004-X

10.1093/jac/28.suppl_B.83

10.3109/10611869609015970

10.1200/JCO.1999.17.5.1435

10.1200/JCO.1999.17.5.1425

10.1016/S0960-9776(01)80001-1

10.1016/S0960-9776(01)80002-3

10.1016/S0960-9776(01)80003-5

10.1016/S0960-9776(01)80004-7

10.1016/S0960-9776(01)80005-9

Federico M., 2001, In: Therapy perspectives,, 1

Cowens J.W., 1993, Cancer Res,, 53, 2796

10.1021/bc00017a001

Jain R.K., 1990, Cancer Res,, 50, 814S

Gabizon A.A., 1994, Hematol Oncol Clin North Am,, 8, 431

10.1016/0009-3084(86)90079-4

10.1016/0378-5173(87)90034-2

Chonn A., 1992, J Biol Chem,, 267, 18759, 10.1016/S0021-9258(19)37026-7

10.1016/0005-2736(94)90231-3

Senior J.H., 1987, Crit Rev Ther Drug Carrier Syst,, 3, 123

Chow D.D., 1989, J Pharmacol Exp Ther,, 248, 506

10.1016/0304-4165(85)90174-6

Michieli M., 1999, Haematologica,, 84, 1151

10.1200/JCO.1995.13.4.996

10.3109/08982109409037058

Forssen E.A., 1996, Cancer Res,, 56, 2066

10.1046/j.1365-2141.1999.01505.x

10.1073/pnas.85.18.6949

10.1016/0005-2736(89)90078-3

10.1248/cpb.38.1663

10.1016/0005-2760(92)90238-Q

10.1016/0378-5173(94)00188-B

10.1016/0005-2736(90)90440-Y

10.1016/0005-2736(91)90246-5

10.1016/0014-5793(90)81016-H

10.1016/0304-4157(92)90038-C

10.1016/0169-409X(95)00028-6

10.1016/S0169-409X(96)00456-5

10.2165/00003495-199753030-00011

Martin FJ., 1997, Oncology, 11, 11

Gabizon A., 1994, Cancer Res,, 54, 987

10.3109/02841869409083948

10.1002/jps.2600820617

10.1007/BF00685327

10.3109/10611869408996815

10.1002/j.1552-4604.1996.tb04152.x

10.1038/bjc.1991.476

10.1016/S0169-409X(96)00476-0

10.1016/S0378-5173(97)00415-8

10.1200/JCO.1995.13.4.914

10.1007/BF00180514

Northfelt D.W., 1997, Oncology,, 11, 21

10.1200/JCO.1998.16.7.2445

10.1200/JCO.1998.16.2.683

10.1200/JCO.1996.14.8.2353

10.2165/00003495-199700544-00006

10.1200/JCO.2000.18.17.3093

10.1200/JCO.2002.08.171

Muggia F.M., 1997, Oncology,, 11, 38

10.1006/gyno.2000.5980

10.1002/1097-0142(20010101)91:1<90::AID-CNCR12>3.0.CO;2-A

10.1200/JCO.1994.12.7.1408

10.3109/08982109909035551

10.1002/(SICI)1097-0142(19990701)86:1<72::AID-CNCR12>3.0.CO;2-1

10.1081/CNV-100103136

10.1200/JCO.1997.15.10.3185

10.1200/JCO.2001.19.6.1716

10.1023/A:1008323200102

Baselga J., 1998, Cancer Res,, 58, 2825

10.1016/S0190-9622(00)90007-0

10.1097/00001813-200002000-00009

10.1023/A:1008319618638

10.1023/A:1008394125040

10.1200/JCO.1995.13.7.1777

10.2165/00128071-200001040-00004

10.2165/00003495-199700544-00007

10.1002/1097-0142(19950415)75:8<2169::AID-CNCR2820750822>3.0.CO;2-H

10.1002/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z

10.1016/S0140-6736(05)65133-1

10.1007/s002800050591

10.1093/jnci/87.20.1556

10.1023/A:1008365716693

10.1016/S0168-3659(01)00315-7

10.1016/0165-6147(94)90314-X

10.1021/js9604467

10.1038/bjc.1996.625

10.1016/S0169-409X(97)00083-5

10.1042/bst0231067

10.1615/CritRevTherDrugCarrierSyst.v15.i6.20

10.1021/ja952725m

10.1016/S0169-409X(99)00034-4

10.1002/1520-6017(200011)89:11<1452::AID-JPS8>3.0.CO;2-P

10.1016/S0168-3659(99)00198-4

10.1016/S0168-3659(99)00166-2

Gao X., 1995, Gene Ther,, 2, 710

Ogihara-Umeda I., 1996, J Nucl Med,, 37, 326

10.1016/0969-8051(93)90107-6

10.3109/10611869608996824

10.1016/S0169-409X(98)00110-0

10.1016/S0145-2126(97)00160-4

van Bree C., 1996, Cancer Res,, 56, 563

Thông tin
Thông tin xuất bản

Tumori

Tập 89 Số 3

237-249

Thông tin tác giả